GlassScriptPhysician profile
Nathan A Phelps
NPI 1255628996
$10,962.73
in general payments reported to CMS, 2019-2025
60 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.97 · 2020: $1,846 · 2021: $3,061 · 2022: $1,609 · 2023: $1,687 · 2024: $1,699 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,321 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,320.89 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,232.60 | 2021 | |
| Abbvie INC. | $1,021.89 | 2021-2025 | |
| Lilly USA, LLC | $661.74 | 2020-2025 | Mounjaro, Jardiance, Kisunla |
| Astellas Pharma US INC | $658.26 | 2020-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $632.04 | 2020-2024 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $627.78 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $603.40 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $515.57 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $505.45 | 2020-2024 | |
| Amarin Pharma, INC. | $426.64 | 2020-2022 | |
| Novo Nordisk INC | $419.13 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $414.16 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $391.16 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $303.89 | 2020-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $221.06 | 2020-2023 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Phelps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.